DMC Biotechnologies has appointed K’Lynne Johnson as Chair of its Board of Directors. Johnson has over 25 years of leadership in technology and chemical industries. Her experience includes roles in high-growth startups and large corporations.
This appointment coincides with DMC’s upcoming Series C funding round. The funds aim to support full-scale production and sales growth of its initial products. DMC is focused on expanding its biomanufacturing platform and customer base.
“K’Lynne’s track record in scaling breakthrough technologies and shaping strategy across both startups and global enterprises makes her an ideal leader for our board,” said Jim Flatt, CEO of DMC. “Her guidance will be pivotal as we commercialize products from our biomanufacturing technology platform, expand our customer base, and deliver sustainable solutions at scale.”
Johnson previously served as the founding CEO of Elevance Renewable Sciences. The company specializes in chemicals made from renewable feedstocks. She has also held senior roles at Innovene, BP, and Amoco. Besides her role at DMC, Johnson sits on the boards of FMC Corporation, Trinseo, JM Huber, and BlueScope Steel.
“DMC has built a powerful technology platform with real commercial momentum,” said Johnson. “I’m excited to help the team bring sustainable, scalable alternatives to market and drive meaningful change in the chemical industry.”
DMC’s Series C round will fund product launches and sales expansion. The focus areas include nutrition, personal care, and bio-based materials. The funding will also support new partnerships and scaling manufacturing processes.
DMC aims to lead in sustainable chemical production through its precision fermentation platform. The company is preparing for significant growth in the coming months.
